RPM program · Nephrology

Chronic kidney disease, stages 3 to 4

Slow disease, narrow therapeutic window, and pressure control that has to be verified at home.

CKD is a monitoring problem with a very long time constant, which makes it a poor fit for programs built around alerts and a good fit for programs built around trend integrity. The value is a defensible 90-day pressure trajectory that justifies each titration, plus early detection of the tolerability issues that make patients quit the drugs that actually slow progression.
Chronic kidney disease, stages 3 to 4 · observed transmission profile Representative, not best case
Day 1Day 15Day 30
Transmitted days 0 / 30
Device supply code
Signal stack

What gets measured, from where, and why it earns its place

Every source is tagged at ingest as billable or context-only. Context-only data is clinically valuable and never enters a device-supply line.

Blood pressure
Cellular cuff
The primary modifiable determinant of progression. Home readings are the ones that matter for a population whose office pressures are systematically misleading.
Weight
Connected scale
Volume status, and the denominator for every dose that gets adjusted.
Symptom and adherence check-in
Weekly
Captures the RAAS-inhibitor and SGLT2 tolerability issues that cause silent discontinuation.
Home albumin-creatinine ratio
Cleared home assay where available
Still early. Where a cleared home path exists, it is the highest-value addition to the stack.
Escalation design

Thresholds, and who has to do something about them

Red marks a same-day or immediate pathway. Amber marks a review within the stated window. Each one is assigned to a named clinician with a response clock, not to a queue.

Systolic > 160 on two consecutive readings
ResponseSame-day review
Weight rise > 2 kg in 72 hours
ResponseVolume review, diuretic protocol
Reported adherence < 70% on a RAAS inhibitor
ResponseReview before the next lab draw
Symptomatic hypotension reported
ResponseSame-day dose review

What we will not oversell

Laboratory values are not remote physiologic monitoring. Gathermed merges lab results into the timeline for clinical context; they do not contribute to a device-supply line.

Program operation

How the month actually runs

Enroll at stage 3b or on initiation of a kidney-protective agent.
Cuff plus scale. Resist adding devices nobody reads.
Rolling 28-day pressure mean is the clinical object, not individual readings.
Titration and deprescribing decisions recorded against the trend.
Monthly management time and interactive communication.
Code path · CY2026

What this program can bill

Rates are national non-facility averages, rounded, for orientation. They vary by locality and payer. Verify against your fee schedule before you model revenue on them.

CodeWhat it coversNational avgCadence
99453Setup and patient education
One-time device setup and patient education per episode of care.
$22once per episode
99454Device supply, 16-30 days
Device supply with daily recordings or programmed alerts, 16 or more days of data in 30.
$52per 30 days
99445new 2026Device supply, 2-15 days
New for 2026. Device supply where 2 to 15 days of data were transmitted in 30. Paid at the same rate as 99454. Mutually exclusive with 99454.
$52per 30 days
99457Treatment management, first 20 min
Clinical staff or QHP time, 20 minutes, with at least one interactive communication.
$52per calendar month
99458Treatment management, each additional 20 min
Add-on to 99457. Reported per additional 20 minutes in the month.
$41per additional 20 min
99091Data collection and interpretation, 30 min
QHP collection and interpretation of physiologic data. Cannot be stacked with 99457/99458 for the same service period.
$58per 30 days

Diagnosis anchors

ICD-10-CMDescription
N18.30Chronic kidney disease, stage 3 unspecified
N18.4Chronic kidney disease, stage 4
E11.22Type 2 diabetes with diabetic chronic kidney disease

Illustrative anchors only. Code to the documented clinical picture, not to a list on a vendor website.

The rules that break programs

One billing clinician per 30-day episode. RPM and RTM are not additive in the same calendar month. Duration codes are mutually exclusive. Management time requires at least one real-time interactive communication. Medical necessity precedes enrollment.

Full rule set and calculator

Sponsor view

If you are a manufacturer looking at this condition

Kidney-protective therapy has a persistence problem driven by an early creatinine bump that frightens patients and clinicians, plus hyperkalemia management. A sponsored program produces the discontinuation timing and reasons, home pressure response, and the fraction of stops that were clinically unnecessary. Relevant to SGLT2 inhibitors, nonsteroidal MRAs, and endothelin-targeted agents.

Read this before you fund anything

Sponsor-funded monitoring that produces billable revenue for prescribers is remuneration to referral sources under the federal Anti-Kickback Statute. The structures that survive scrutiny keep the sponsor's data interest and the provider's billing interest completely separate. The three structures we will build, and the one we will not.

Questions

Chronic kidney disease, stages 3 to 4 monitoring, answered directly

Can lab results count toward RPM?
No. The device-supply codes require a cleared device transmitting physiologic data. Labs are context, and valuable context, but not billable under this family.